Analysts expect Trinity Biotech Plc to report revenue of 15.25 M for Q1 25, against a range of 14.23 M to 16.26 M. The most recent reported quarter, Q4 24, came in at 15.86 M, a 6.2% miss against the 16.90 M consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 15.84 M | 15.15 M | 15.86 M | - | - | - | - | - | - | - | - | ||||
| High Estimate | 17.12 M | 18.33 M | 17.86 M | 16.26 M | 11.66 M | 14.35 M | 15.50 M | 17.62 M | 11.48 M | 15.01 M | 16.03 M | ||||
| Low Estimate | 14.59 M | 15.35 M | 15.95 M | 14.23 M | 10.65 M | 12.83 M | 13.51 M | 16.28 M | 9.98 M | 13.15 M | 14.32 M | ||||
| Consensus Estimate | 15.86 M | 16.84 M | 16.90 M | 15.25 M | 11.15 M | 13.59 M | 14.50 M | 16.95 M | 10.73 M | 14.08 M | 15.17 M |
Analysts expect Trinity Biotech Plc to report earnings per share of -8.75 for Q1 25, against a range of -9.45 to -8.05. The most recent reported quarter, Q4 24, came in at -37.06, a 324.0% miss against the -8.74 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -21.42 | -13.74 | -37.06 | - | - | - | - | - | - | - | - | ||||
| High Estimate | -20.29 | -14.23 | -8.27 | -8.05 | -14.76 | -9.94 | -8.16 | -8.53 | -7.79 | -7.73 | -6.30 | ||||
| Low Estimate | -22.33 | -16.75 | -9.21 | -9.45 | -16.86 | -11.22 | -9.80 | -9.67 | -8.43 | -8.49 | -7.68 | ||||
| Consensus Estimate | -21.31 | -15.49 | -8.74 | -8.75 | -15.81 | -10.58 | -8.98 | -9.10 | -8.11 | -8.11 | -6.99 |